| Year |
Citation |
Score |
| 2022 |
Stackhouse CT, Anderson JC, Yue Z, Nguyen T, Eustace NJ, Langford CP, Wang J, Rowland Iv JR, Xing C, Mikhail FM, Cui X, Alrefai H, Bash RE, Lee KJ, Yang ES, ... ... Miller CR, et al. An in vivo model of glioblastoma radiation resistance identifies long non-coding RNAs and targetable kinases. Jci Insight. PMID 35852875 DOI: 10.1172/jci.insight.148717 |
0.446 |
|
| 2020 |
Buckley A, Hagler SB, Lettry V, Bagó JR, Maingi SM, Khagi S, Ewend MG, Miller CR, Hingtgen SD. Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32402245 DOI: 10.1016/J.Ymthe.2020.04.022 |
0.391 |
|
| 2020 |
Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Lau CC, Ngan CY, Chapman M, ... ... Miller CR, et al. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell. 37: 243-257.e7. PMID 32049048 DOI: 10.1016/J.Ccell.2020.01.004 |
0.303 |
|
| 2019 |
Miller AD, Miller CR, Rossmeisl JH. Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors. Frontiers in Oncology. 9: 1151. PMID 31788444 DOI: 10.3389/Fonc.2019.01151 |
0.351 |
|
| 2019 |
Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY. Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. Neuro-Oncology. PMID 30753579 DOI: 10.1093/Neuonc/Noz033 |
0.36 |
|
| 2019 |
Smithberger E, Shelton AK, Butler MK, Flores AR, Bash RE, Angus SP, Sciaky N, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 3019: Dynamic kinome profiling of EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy Cancer Research. 79: 3019-3019. DOI: 10.1158/1538-7445.Sabcs18-3019 |
0.334 |
|
| 2019 |
Skinner K, Ferris M, Bash R, Shelton A, Smithberger E, Angus S, Golitz B, Sciaky N, Simon J, Stein J, Matsushima G, Ostrom Q, Stetson L, Barnholtz-Sloan J, Dhruv H, ... ... Miller CR, et al. Abstract 2745: Tumor microenvironment and host genetics impact glioma progression in a Collaborative Cross-based orthotopic allograft model Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2745 |
0.311 |
|
| 2019 |
Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson GL, Berens ME, Furnari F, Miller CR. Abstract 331: Dynamic kinome targeting reveals kinases involved in acquired resistance to tyrosine kinase inhibitors in EGFR-driven glioblastomas Cancer Research. 79: 331-331. DOI: 10.1158/1538-7445.Am2019-331 |
0.302 |
|
| 2018 |
Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, et al. A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology. PMID 30239918 DOI: 10.1093/Jnen/Nly085 |
0.335 |
|
| 2018 |
Okolie O, Irvin DM, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dumitru R, Elton S, Ewend MG, Miller CR, Hingtgen SD. Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection. Plos One. 13: e0198596. PMID 29990322 DOI: 10.1371/Journal.Pone.0198596 |
0.35 |
|
| 2018 |
McNeill RS, Stroobant EE, Smithberger E, Canoutas DA, Butler MK, Shelton AK, Patel SD, Limas JC, Skinner KR, Bash RE, Schmid RS, Miller CR. PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. Plos One. 13: e0200014. PMID 29975751 DOI: 10.1371/Journal.Pone.0200014 |
0.328 |
|
| 2018 |
Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow KL, Wilson GD, Miller CR, Chinnaiyan P. Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29691296 DOI: 10.1158/1078-0432.Ccr-18-0041 |
0.304 |
|
| 2018 |
Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, ... Miller CR, et al. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications. 9: 1057. PMID 29535300 DOI: 10.1038/S41467-018-03476-6 |
0.341 |
|
| 2018 |
Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma. Scientific Reports. 8: 1180. PMID 29352201 DOI: 10.1038/S41598-018-19451-6 |
0.36 |
|
| 2018 |
Kesawani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow K, Wilson G, Miller CR, Chinnaiyan P. Abstract 2763: Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma Cancer Research. 78: 2763-2763. DOI: 10.1158/1538-7445.Am2018-2763 |
0.328 |
|
| 2018 |
Smithberger E, Flores AR, Butler MK, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 2372: Kinome profiling of non-germline, genetically engineered mouse models of glioblastoma driven by Cdkn2a, Egfr, and/or Pten mutations reveals genotype-dependent kinase targets Cancer Research. 78: 2372-2372. DOI: 10.1158/1538-7445.Am2018-2372 |
0.342 |
|
| 2017 |
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, ... ... Miller CR, et al. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine. 9. PMID 28539475 DOI: 10.1126/Scitranslmed.Aal4682 |
0.314 |
|
| 2017 |
Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, et al. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-Oncology. PMID 28486691 DOI: 10.1093/Neuonc/Nox052 |
0.318 |
|
| 2017 |
McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AE, ... ... Miller CR, et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology. PMID 28379424 DOI: 10.1093/Neuonc/Nox044 |
0.309 |
|
| 2017 |
Bagó JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Werff RV, Underhill TM, Schmid RS, Miller CR, Hingtgen SD. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. 9. PMID 28148846 DOI: 10.1126/Scitranslmed.Aah6510 |
0.35 |
|
| 2017 |
Swearingen AEDV, Sambade MJ, Siegel MB, Sud S, Bevill SM, Golitz BT, Bash RE, Santos CM, Darr DB, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A03 |
0.36 |
|
| 2016 |
Okolie O, Bago JR, Schmid RS, Irvin DM, Bash RE, Miller CR, Hingtgen SD. Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model. Neuro-Oncology. PMID 27298311 DOI: 10.1093/Neuonc/Now117 |
0.309 |
|
| 2016 |
LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE, Levine JM, Simpson RM, Halsey C, Kisseberth W, Rossmeisl JH, et al. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro-Oncology. PMID 27179361 DOI: 10.1093/Neuonc/Now051 |
0.337 |
|
| 2016 |
Bagó JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS, Miller CR, Magness ST, Hingtgen SD. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nature Communications. 7: 10593. PMID 26830441 DOI: 10.1038/Ncomms10593 |
0.344 |
|
| 2016 |
Irvin DM, McNeill RS, Bash RE, Miller CR. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathology (Zurich, Switzerland). PMID 26762242 DOI: 10.1111/Bpa.12348 |
0.333 |
|
| 2016 |
Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Buckner JC, Ligon KL, Ballman KV, Moore DF, Schiff D, Ahluwalia MS, Lee EQ, Horvath LE, Gerstner ER, Lesser GJ, Prados M, et al. Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902. Journal of Clinical Oncology. 34: 2029-2029. DOI: 10.1200/Jco.2016.34.15_Suppl.2029 |
0.308 |
|
| 2015 |
Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, ... ... Miller CR, et al. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14: 920-30. PMID 25824335 DOI: 10.1158/1535-7163.Mct-14-0474 |
0.349 |
|
| 2015 |
McNeill RS, Vitucci M, Wu J, Miller CR. Contemporary murine models in preclinical astrocytoma drug development. Neuro-Oncology. 17: 12-28. PMID 25246428 DOI: 10.1093/Neuonc/Nou288 |
0.345 |
|
| 2015 |
Swearingen AEDV, Siegel MB, Sambade MJ, Sud S, Miller SM, Silva G, Bash RE, Santos CM, Darr DB, Golitz B, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models Cancer Research. 75: 2579-2579. DOI: 10.1158/1538-7445.Am2015-2579 |
0.38 |
|
| 2015 |
Schmid R, Vitucci M, McNeill R, Bash R, Werneke A, Huey L, White K, Ewend M, Wu J, Miller CR. CSIG-14DE-DIFFERENTIATION OF ASTROCYTES INTO GLIOBLASTOMA STEM CELLS THROUGH CORE PATHWAY MUTATIONS Neuro-Oncology. 17: v68.4-v68. DOI: 10.1093/Neuonc/Nov210.14 |
0.343 |
|
| 2015 |
McNeill RS, Canoutas DA, Schmid RS, Bash RE, Constance BH, Azam SH, Reuther RA, Johnson GL, Miller CR. Atps-55Influence Of Mapk And Pi3K Pathway Mutations On Response To Targeted Inhibitors Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.55 |
0.321 |
|
| 2014 |
Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, Verhaak RG, Nishiyama A, Miller CR, Zong H. Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proceedings of the National Academy of Sciences of the United States of America. 111: E4214-23. PMID 25246577 DOI: 10.1073/Pnas.1414389111 |
0.339 |
|
| 2014 |
Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6083-95. PMID 25231403 DOI: 10.1158/1078-0432.Ccr-14-0493 |
0.334 |
|
| 2014 |
McNeill RS, Schmid RS, Bash RE, Vitucci M, White KK, Werneke AM, Constance BH, Huff B, Miller CR. Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice. Journal of Visualized Experiments : Jove. e51763. PMID 25146643 DOI: 10.3791/51763 |
0.362 |
|
| 2014 |
Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. European Urology. 66: 77-84. PMID 24613583 DOI: 10.1016/J.Eururo.2014.02.035 |
0.338 |
|
| 2014 |
Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, Miller CR, Jin J, Darr D, Perou CM, Levine RL, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. The Journal of Clinical Investigation. 124: 553-63. PMID 24435044 DOI: 10.1172/Jci69804 |
0.345 |
|
| 2014 |
Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-Oncology. 16: 173-8. PMID 24305708 DOI: 10.1093/Neuonc/Not229 |
0.349 |
|
| 2014 |
Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, et al. αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 56-67. PMID 24132917 DOI: 10.1158/1078-0432.Ccr-13-1255 |
0.314 |
|
| 2014 |
Swearingen AEDV, Siegel MB, Bash R, Golitz B, Santos C, Darr D, Parker J, Johnson GL, Miller CR, Anders CK. Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-5449A |
0.368 |
|
| 2014 |
Wu J, Huey L, Bash RE, Cohen SM, Ewend MG, Wang X, Graham DK, Frye SV, Earp HS, Miller CR. NT-38 * MerTK AS A TARGET IN GLIOBLASTOMA Neuro-Oncology. 16: v166-v167. DOI: 10.1093/Neuonc/Nou265.36 |
0.377 |
|
| 2014 |
Irvin D, Schmid R, Bash R, Miller CR. Me-07Influence Of Regional Microenviroment And Astrocyte Heterogeneity On Astrocytoma Development Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou261.6 |
0.329 |
|
| 2013 |
Huff LP, Decristo MJ, Trembath D, Kuan PF, Yim M, Liu J, Cook DR, Miller CR, Der CJ, Cox AD. The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes & Cancer. 4: 460-75. PMID 24386507 DOI: 10.1177/1947601913514851 |
0.307 |
|
| 2013 |
Song Y, Zhang Q, Kutlu B, Difilippantonio S, Bash R, Gilbert D, Yin C, O'Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN, Miller CR, et al. Evolutionary etiology of high-grade astrocytomas. Proceedings of the National Academy of Sciences of the United States of America. 110: 17933-8. PMID 24114272 DOI: 10.1073/Pnas.1317026110 |
0.331 |
|
| 2013 |
Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, Aldape KD, McLendon RE, Lehman NL, Miller CR, Schniederjan MJ, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4951-60. PMID 23864165 DOI: 10.1158/1078-0432.Ccr-13-0551 |
0.378 |
|
| 2013 |
Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro-Oncology. 15: 1317-29. PMID 23814263 DOI: 10.1093/Neuonc/Not084 |
0.315 |
|
| 2013 |
Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, et al. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. The Journal of Molecular Diagnostics : Jmd. 15: 485-97. PMID 23701907 DOI: 10.1016/J.Jmoldx.2013.03.007 |
0.371 |
|
| 2013 |
Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. Plos One. 8: e61359. PMID 23650496 DOI: 10.1371/Journal.Pone.0061359 |
0.332 |
|
| 2013 |
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/Jci67816 |
0.362 |
|
| 2013 |
Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. The Journal of Clinical Investigation. 123: 2078-93. PMID 23563312 DOI: 10.1172/Jci66715 |
0.355 |
|
| 2013 |
Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, ... ... Miller CR, et al. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathology (Zurich, Switzerland). 23: 584-94. PMID 23452038 DOI: 10.1111/Bpa.12050 |
0.339 |
|
| 2013 |
Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nature Communications. 4: 1449. PMID 23385593 DOI: 10.1038/Ncomms2438 |
0.329 |
|
| 2013 |
Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, ... ... Miller CR, et al. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Archives of Pathology & Laboratory Medicine. 137: 32-40. PMID 22583114 DOI: 10.5858/Arpa.2012-0033-Oa |
0.313 |
|
| 2013 |
Schlegel J, Sambade M, Sather S, Moschos S, Tan A, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt G, Kuan P, Hamilton RL, Duncan LM, Miller CR, et al. Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. Cancer Research. 73: 3037-3037. DOI: 10.1158/1538-7445.Am2013-3037 |
0.345 |
|
| 2012 |
Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 21: 751-64. PMID 22698401 DOI: 10.1016/J.Ccr.2012.03.048 |
0.344 |
|
| 2012 |
Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. Plos One. 7: e36530. PMID 22590557 DOI: 10.1371/Journal.Pone.0036530 |
0.361 |
|
| 2012 |
Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 21: 155-67. PMID 22340590 DOI: 10.1016/J.Ccr.2011.12.021 |
0.396 |
|
| 2012 |
Schmid RS, Vitucci M, Miller CR. Genetically engineered mouse models of diffuse gliomas. Brain Research Bulletin. 88: 72-9. PMID 21684324 DOI: 10.1016/J.Brainresbull.2011.06.002 |
0.342 |
|
| 2012 |
DeCristo MJ, Parker LE, Trembath D, Kuan P, Yim M, Liu J, Miller CR, Der CJ, Cox AD. Abstract LB-30: A functional analysis of the nuclear RhoGEF Ect2 in ovarian cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-30 |
0.331 |
|
| 2012 |
Vitucci M, Huff B, Bash RE, Karpinich NO, Schmid RS, Miller CR. Abstract 4305: Dissecting the requirements for astrocytoma and invasion using genetically-engineered mouse models Cancer Research. 72: 4305-4305. DOI: 10.1158/1538-7445.Am2012-4305 |
0.34 |
|
| 2012 |
Schmid RS, Bash RE, Werneke AM, Miller CR. Abstract 3302: Roles of cortical and subventricular GFAP+ astrocytes in initiation of astrocytomas Cancer Research. 72: 3302-3302. DOI: 10.1158/1538-7445.Am2012-3302 |
0.33 |
|
| 2011 |
Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM, Der CJ. RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small Gtpases. 2: 202-210. PMID 22145092 DOI: 10.4161/Sgtp.2.4.17795 |
0.336 |
|
| 2011 |
Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Research : Bcr. 13: R125. PMID 22132754 DOI: 10.1186/Bcr3071 |
0.326 |
|
| 2011 |
Ang MK, Patel MR, Yin XY, Sundaram S, Fritchie K, Zhao N, Liu Y, Freemerman AJ, Wilkerson MD, Walter V, Weissler MC, Shockley WW, Couch ME, Zanation AM, Hackman T, ... ... Miller CR, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6542-52. PMID 21908577 DOI: 10.1158/1078-0432.Ccr-10-1604 |
0.311 |
|
| 2011 |
Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 117: 1602-11. PMID 21472708 DOI: 10.1002/Cncr.25746 |
0.316 |
|
| 2011 |
Horbinski C, Miller CR, Perry A. Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathology (Zurich, Switzerland). 21: 57-73. PMID 21129060 DOI: 10.1111/J.1750-3639.2010.00453.X |
0.494 |
|
| 2011 |
Dellon ES, Chen X, Miller CR, Fritchie KJ, Rubinas TC, Woosley JT, Shaheen NJ. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. The American Journal of Gastroenterology. 106: 264-71. PMID 20978486 DOI: 10.1038/Ajg.2010.412 |
0.309 |
|
| 2010 |
Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4864-75. PMID 20643781 DOI: 10.1158/1078-0432.Ccr-10-0199 |
0.364 |
|
| 2010 |
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110. PMID 20129251 DOI: 10.1016/J.Ccr.2009.12.020 |
0.338 |
|
| 2010 |
Song Y, Zhang Q, Miller CR, Threadgill D, McCarthy KD, Dyke TV. Abstract LB-150: Role of EGFR signaling in an inducible mouse model of astrocytomas Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-150 |
0.382 |
|
| 2010 |
Wilkerson MD, Yin X, Hayward MC, Funkhouser WK, Thorne L, Parsons AM, Miller CR, Socinski MA, Bernard PS, Perou CM, Hayes DN. Abstract 2164: Lung adenocarcinoma subtypes have unique gene mutations (EGFR, TP53), DNA copy number alterations (3q26, 16p13), and patient smoking histories Cancer Research. 70: 2164-2164. DOI: 10.1158/1538-7445.Am10-2164 |
0.314 |
|
| 2009 |
Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblum MK. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathology (Zurich, Switzerland). 19: 81-90. PMID 18452568 DOI: 10.1111/J.1750-3639.2008.00167.X |
0.498 |
|
| 2008 |
Trembath D, Miller CR, Perry A. Gray zones in brain tumor classification: evolving concepts. Advances in Anatomic Pathology. 15: 287-97. PMID 18724102 DOI: 10.1097/Pap.0B013E3181836A03 |
0.426 |
|
| 2008 |
Goodgame B, Viswanathan A, Miller CR, Gao F, Meyers B, Battafarano RJ, Patterson A, Cooper J, Guthrie TJ, Bradley J, Pillot G, Govindan R. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. American Journal of Clinical Oncology. 31: 22-8. PMID 18376223 DOI: 10.1097/Coc.0B013E3180Ca77D1 |
0.318 |
|
| 2007 |
Miller CR, Perry A. Glioblastoma. Archives of Pathology & Laboratory Medicine. 131: 397-406. PMID 17516742 DOI: 10.1043/1543-2165(2007)131[397:G]2.0.Co;2 |
0.489 |
|
| 2007 |
Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapy-induced toxicity. The Journal of Supportive Oncology. 5: 9-14. PMID 17265780 |
0.366 |
|
| 2007 |
Miller CR, Haddix T, Dunham CP, Perry A. Clinical significance of prospective molecular genetic analysis of glial neoplasms: the Washington University FISH laboratory experience Journal of Neuropathology and Experimental Neurology. 66: 426. DOI: 10.1097/01.Jnen.0000268836.67111.A3 |
0.43 |
|
| 2007 |
Miller CR, Haddix T, Dunham CP, Perry A. Clinical significance of prospective molecular genetic analysis of glial neoplasms: The Washington University FISH Laboratory experience The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A26-A |
0.43 |
|
| 2006 |
Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5419-26. PMID 17135643 DOI: 10.1200/Jco.2006.08.1497 |
0.462 |
|
| 2005 |
Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Therapy. 12: 284-94. PMID 15650766 DOI: 10.1038/Sj.Cgt.7700750 |
0.363 |
|
| 2004 |
Miller CR, Perry A. CD34 and MAP-2 Immunohistochemistry in the Differential Diagnosis of Epilepsy-Associated Glioneuronal Tumors Advances in Anatomic Pathology. 11: 326-327. DOI: 10.1097/01.Pap.0000146224.33552.F0 |
0.437 |
|
| 2004 |
Miller CR, Perry A. Immunohistochemical Differentiation of Hemangioblastoma from Metastatic Clear Cell Renal Carcinoma: An Update Advances in Anatomic Pathology. 11: 325-326. DOI: 10.1097/01.Pap.0000146223.33552.3E |
0.412 |
|
| 2002 |
Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Molecular Cancer Therapeutics. 1: 1139-45. PMID 12481438 |
0.57 |
|
| 2002 |
Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Research. 62: 773-80. PMID 11830532 |
0.629 |
|
| 2002 |
Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Analytical Biochemistry. 301: 189-99. PMID 11814289 DOI: 10.1006/Abio.2001.5511 |
0.505 |
|
| 2000 |
Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4323-33. PMID 11106250 |
0.586 |
|
| 1999 |
Blackwell JL, Miller CR, Douglas JT, Li H, Reynolds PN, Carroll WR, Peters GE, Strong TV, Curiel DT. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Archives of Otolaryngology--Head & Neck Surgery. 125: 856-63. PMID 10448731 DOI: 10.1001/Archotol.125.8.856 |
0.502 |
|
| 1999 |
Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V, Curiel DT. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nature Biotechnology. 17: 470-5. PMID 10331807 DOI: 10.1038/8647 |
0.473 |
|
| 1998 |
Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research. 58: 5738-48. PMID 9865732 |
0.644 |
|
| 1998 |
Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology. 72: 9706-13. PMID 9811704 DOI: 10.1128/Jvi.72.12.9706-9713.1998 |
0.503 |
|
| 1998 |
Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. Journal of Virology. 72: 1844-52. PMID 9499035 DOI: 10.1128/Jvi.72.3.1844-1852.1998 |
0.429 |
|
| Show low-probability matches. |
